Q&A With Aaron Boster From OhioHealth Neurological Physicians: Finding the Right Chili Recipe For Treating Multiple Sclerosis Depends A Lot On Open Communication

Video

As the number of treatment options for multiple sclerosis continues to grow patients and their doctors are left to find the right choice for them in order to manage the disease as successfully as possible. This can be a long process that can have a long lasting impact on their overall health.

With a wide variety of medications available and being developed for patients with multiple sclerosis the choices present different delivery options, dosing varieties, and other options. Alemtuzumab is another in this series of exciting developments in potential patient care.

Aaron L. Boster, MD, From OhioHealth Neurological Physicians discussed the treatment and finding the best treatment options avaialbe to patients during the annual ECTRIMS conference in Barcelona.

As the number of treatment options for multiple sclerosis continues to grow patients and their doctors are left to find the right choice for them in order to manage the disease as successfully as possible. This can be a long process that can have a long lasting impact on their overall health.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.